These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2284 related articles for article (PubMed ID: 24140091)

  • 1. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort.
    Kashyap SR; Diab DL; Baker AR; Yerian L; Bajaj H; Gray-McGuire C; Schauer PR; Gupta M; Feldstein AE; Hazen SL; Stein CM
    Obesity (Silver Spring); 2009 Sep; 17(9):1696-701. PubMed ID: 19360015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
    Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
    Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum homocysteine levels in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Patsiaoura K; Katsiki E; Zafeiriadou E; Deretzi G; Zavos C; Gavalas E; Katsinelos P; Mane V; Slavakis A
    Ann Hepatol; 2012; 11(1):68-76. PubMed ID: 22166563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 6. Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease.
    Pacifico L; Bezzi M; Lombardo CV; Romaggioli S; Ferraro F; Bascetta S; Chiesa C
    World J Gastroenterol; 2013 Jul; 19(25):4007-14. PubMed ID: 23840146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum chemerin and vaspin in non-alcoholic fatty liver disease.
    Kukla M; Zwirska-Korczala K; Hartleb M; Waluga M; Chwist A; Kajor M; Ciupinska-Kajor M; Berdowska A; Wozniak-Grygiel E; Buldak R
    Scand J Gastroenterol; 2010; 45(2):235-42. PubMed ID: 20095887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents.
    de Piano A; de Mello MT; Sanches Pde L; da Silva PL; Campos RM; Carnier J; Corgosinho F; Foschini D; Masquio DL; Tock L; Oyama LM; do Nascimento CM; Tufik S; Dâmaso AR
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1313-24. PubMed ID: 22932160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
    Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease.
    Lebensztejn DM; Wojtkowska M; Skiba E; Werpachowska I; Tobolczyk J; Kaczmarski M
    Adv Med Sci; 2009; 54(2):177-82. PubMed ID: 20022856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
    Mager DR; Yap J; Rodriguez-Dimitrescu C; Mazurak V; Ball G; Gilmour S
    Nutr Clin Pract; 2013 Feb; 28(1):101-11. PubMed ID: 23042833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.
    Bekaert M; Ouwens DM; Hörbelt T; Van de Velde F; Fahlbusch P; Herzfeld de Wiza D; Van Nieuwenhove Y; Calders P; Praet M; Hoorens A; Geerts A; Verhelst X; Kaufman JM; Lapauw B
    Obesity (Silver Spring); 2016 Dec; 24(12):2544-2552. PubMed ID: 27768254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma adiponectin is decreased in nonalcoholic fatty liver disease.
    Pagano C; Soardo G; Esposito W; Fallo F; Basan L; Donnini D; Federspil G; Sechi LA; Vettor R
    Eur J Endocrinol; 2005 Jan; 152(1):113-8. PubMed ID: 15762194
    [TBL] [Abstract][Full Text] [Related]  

  • 15.  Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Polymerou V; Papadimitriou KG; Zavos C; Katsinelos P
    Ann Hepatol; 2016; 15(5):705-14. PubMed ID: 27493109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis?
    Cengiz C; Ardicoglu Y; Bulut S; Boyacioglu S
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):813-9. PubMed ID: 19820404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
    Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?
    Yang S; Wang Q; Huang W; Song Y; Feng G; Zhou L; Tan J
    Gynecol Endocrinol; 2016; 32(1):38-41. PubMed ID: 26291816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis.
    Muñoz LE; Cordero P; Torres L; Sauceda AY; Flores JP; Segura JJ
    Ann Hepatol; 2009; 8(2):123-8. PubMed ID: 19502655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 115.